These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23109677)

  • 1. Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: a modern paradigm shift.
    Vlassara H; Cai W; Chen X; Serrano EJ; Shobha MS; Uribarri J; Woodward M; Striker GE
    J Gerontol A Biol Sci Med Sci; 2012 Dec; 67(12):1410-6. PubMed ID: 23109677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease.
    Vlassara H; Uribarri J; Cai W; Goodman S; Pyzik R; Post J; Grosjean F; Woodward M; Striker GE
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):934-42. PubMed ID: 22461535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
    Rastogi A
    Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease.
    Yubero-Serrano EM; Woodward M; Poretsky L; Vlassara H; Striker GE;
    Clin J Am Soc Nephrol; 2015 May; 10(5):759-66. PubMed ID: 25710801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying advanced glycation end products as a major source of oxidants in aging: implications for the management and/or prevention of reduced renal function in elderly persons.
    Vlassara H; Uribarri J; Ferrucci L; Cai W; Torreggiani M; Post JB; Zheng F; Striker GE
    Semin Nephrol; 2009 Nov; 29(6):594-603. PubMed ID: 20006791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging effects of sevelamer in chronic kidney disease.
    Ikee R; Tsunoda M; Sasaki N; Sato N; Hashimoto N
    Kidney Blood Press Res; 2013; 37(1):24-32. PubMed ID: 23486088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study.
    Ruggeri M; Cipriani F; Bellasi A; Russo D; Di Iorio B
    Blood Purif; 2014; 37(4):316-24. PubMed ID: 25171148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging.
    Vlassara H; Torreggiani M; Post JB; Zheng F; Uribarri J; Striker GE
    Kidney Int Suppl; 2009 Dec; (114):S3-11. PubMed ID: 19946325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation.
    Brandenburg VM; Jahnen-Dechent W; Ketteler M
    Kidney Int Suppl; 2009 Dec; (114):S26-33. PubMed ID: 19946324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis.
    Chennasamudram SP; Noor T; Vasylyeva TL
    J Ren Care; 2013 Jun; 39(2):82-9. PubMed ID: 23574727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism.
    Phelps KR; Stote KS; Mason D
    Clin Nephrol; 2014 Sep; 82(3):191-201. PubMed ID: 25079864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
    Ruggiero B; Trillini M; Tartaglione L; Rotondi S; Perticucci E; Tripepi R; Aparicio C; Lecchi V; Perna A; Peraro F; Villa D; Ferrari S; Cannata A; Mazzaferro S; Mallamaci F; Zoccali C; Bellasi A; Cozzolino M; Remuzzi G; Ruggenenti P; Kohan DE;
    Am J Kidney Dis; 2019 Sep; 74(3):338-350. PubMed ID: 31027883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
    Thompson M; Bartko-Winters S; Bernard L; Fenton A; Hutchison C; Di Iorio B
    J Med Econ; 2013; 16(6):744-55. PubMed ID: 23550810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced glycation end products and arterial stiffness in patients with diabetic nephropathy and patients with chronic kidney disease without diabetes.
    Stróżecki P; Kurowski R; Flisiński M; Stefańska A; Odrowąż-Sypniewska G; Manitius J
    Pol Arch Med Wewn; 2013; 123(11):609-16. PubMed ID: 24036618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia.
    Stinghen AE; Gonçalves SM; Bucharles S; Branco FS; Gruber B; Hauser AB; Pecoits-Filho R
    Blood Purif; 2010; 29(4):352-6. PubMed ID: 20357435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study.
    Lemos MM; Watanabe R; Carvalho AB; Jancikic AD; Sanches FM; Christofalo DM; Draibe SA; Canziani ME
    Clin Nephrol; 2013 Jul; 80(1):1-8. PubMed ID: 23442255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endotoxin-binding affinity of sevelamer: a potential novel anti-inflammatory mechanism.
    Sun PP; Perianayagam MC; Jaber BL
    Kidney Int Suppl; 2009 Dec; (114):S20-5. PubMed ID: 19946323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.
    Kakuta T; Tanaka R; Hyodo T; Suzuki H; Kanai G; Nagaoka M; Takahashi H; Hirawa N; Oogushi Y; Miyata T; Kobayashi H; Fukagawa M; Saito A
    Am J Kidney Dis; 2011 Mar; 57(3):422-31. PubMed ID: 21239096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.